Idylla EGFR Lung Trial
Technology Study: Measuring Potential Impact of Research Use Only Rapid EGFR Testing on Standard of Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hannah Park, BS
- Phone Number: 754-242-9682
- Email: hannah.park@proteanbiodx.com
Study Contact Backup
- Name: So Hyeon Park, MS
- Phone Number: 754-242-9682
- Email: sohyeon.park@proteanbiodx.com
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32827
- Recruiting
- 6555 Sanger Rd, Suite 260
-
Contact:
- Hannah Park, BS
- Phone Number: 754-242-9682
- Email: hannah.park@proteanbiodx.com
-
Contact:
- So Hyeon Park, MS
- Phone Number: 754-242-9682
- Email: sohyeon.park@proteanbiodx.com
-
Principal Investigator:
- Anthony Magliocco, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with primary lung cancer
- Data from primary diagnosis must be included in pathology report or data entry.
- Detailed pathology report included for all samples
Exclusion Criteria:
- Limited or no tissue available
- Only tissue available is from fine needle aspiration
- Tissue blocks older than 5 years old
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lung Cancer
The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations.
One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality.
This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.
|
This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Idylla EGFR Mutation Test
Time Frame: Retrospective tissue samples no longer than 5 years old
|
The primary outcome measured is if the Idylla EGFR Mutation Test is a possible alternative to diagnose EGFR mutation status in tissue samples.
|
Retrospective tissue samples no longer than 5 years old
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anthony Magliocco, MD, CEO and Founder
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R20-00012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.